Regeneron
Biotech

Regeneron rides into radiopharma via $2.1B biobucks Telix pact

With its latest obesity play appearing to pay off, Regeneron has turned its attention to radiopharmaceuticals.
James Waldron Apr 13, 2026 7:24am
sailing boat water yacht ocean wind

Seaport, Hemab prepare IPOs to fund depression, clotting drugs

Apr 13, 2026 7:12am
Biotech Giants and Investors Gather to Solve the Commercialisation Puzzle This May in Hong Kong

ASGH 2026: Solving the Biotech Commercialisation Puzzle

GSK ESMO

GSK CEO’s ‘scientific courage’ propels ADC toward ph. 3 tests

Apr 12, 2026 10:10am
Beyond the Hype Turning NAMs into Actionable Evidence

Beyond the Hype: Turning NAMs into Actionable Evidence

Brought to you by Battelle
Amazing landscapes of Appenzell with impressive rock formations and beautiful lakes

Allogene’s off-the-shelf CAR-T erases lingering lymphoma cells

Apr 13, 2026 7:45am
More News

Kailera plans $528.5 million IPO to support obesity assets

Apr 13, 2026 1:10pm

Spyre touts ph. 2 UC win as proof it could surpass Entyvio

Apr 13, 2026 9:55am

Fierce Biotech Fundraising Tracker '26: Neomorph, Oricell & more

Apr 13, 2026 9:50am

AbbVie inks $745M deal with China’s Haisco for two pain assets

Apr 13, 2026 9:48am